Navamedic ASA

OB:NAVA Stock Report

Market Cap: NOK 392.1m

Navamedic Valuation

Is NAVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NAVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
NOK 31.00
Fair Value
28.4% undervalued intrinsic discount
2
Number of Analysts

Below Fair Value: NAVA (NOK22.2) is trading below our estimate of fair value (NOK31)

Significantly Below Fair Value: NAVA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NAVA?

Key metric: As NAVA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NAVA. This is calculated by dividing NAVA's market cap by their current revenue.
What is NAVA's PS Ratio?
PS Ratio0.7x
SalesNOK 542.59m
Market CapNOK 392.11m

Price to Sales Ratio vs Peers

How does NAVA's PS Ratio compare to its peers?

The above table shows the PS ratio for NAVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average17.8x
VISTN Vistin Pharma
2.5xn/aNOK 1.1b
SOFTX SoftOx Solutions
45xn/aNOK 356.2m
ONCIN Oncoinvent
21.1x-8.47%NOK 171.2m
PHO Photocure
2.5x14.01%NOK 1.3b
NAVA Navamedic
0.7x10.77%NOK 392.1m

Price-To-Sales vs Peers: NAVA is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (17.8x).

Price to Sales Ratio vs Industry

How does NAVA's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.2x5.8%
NAVA Navamedic
 0.7x10.77%US$37.53m
NAVA 0.7xIndustry Avg. 3.2xNo. of Companies34PS0612182430+
27 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.2x13.4%
NAVA Navamedic
 0.7x90.44%US$37.53m
No more companies

Price-To-Sales vs Industry: NAVA is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Pharmaceuticals industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is NAVA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NAVA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: NAVA is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NAVA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 22.20
NOK 34.00
+53.15%
5.88%NOK 36.00NOK 32.00n/a2
Apr ’26NOK 22.60
NOK 34.00
+50.44%
5.88%NOK 36.00NOK 32.00n/a2
Mar ’26NOK 21.00
NOK 37.00
+76.19%
2.70%NOK 38.00NOK 36.00n/a2
Feb ’26NOK 24.40
NOK 37.00
+51.64%
2.70%NOK 38.00NOK 36.00n/a2
Jan ’26NOK 25.70
NOK 37.00
+43.97%
2.70%NOK 38.00NOK 36.00n/a2
Dec ’25NOK 25.60
NOK 37.00
+44.53%
2.70%NOK 38.00NOK 36.00n/a2
Nov ’25NOK 25.00
NOK 45.50
+82.00%
1.10%NOK 46.00NOK 45.00n/a2
Oct ’25NOK 30.10
NOK 45.50
+51.16%
1.10%NOK 46.00NOK 45.00n/a2
Sep ’25NOK 29.10
NOK 45.50
+56.36%
1.10%NOK 46.00NOK 45.00n/a2
Aug ’25NOK 32.00
NOK 46.50
+45.31%
1.08%NOK 47.00NOK 46.00n/a2
Jul ’25NOK 33.00
NOK 46.50
+40.91%
1.08%NOK 47.00NOK 46.00n/a2
Jun ’25NOK 33.90
NOK 49.00
+44.54%
6.12%NOK 52.00NOK 46.00n/a2
May ’25NOK 32.40
NOK 49.00
+51.23%
6.12%NOK 52.00NOK 46.00NOK 21.902
Apr ’25NOK 35.60
NOK 51.00
+43.26%
1.96%NOK 52.00NOK 50.00NOK 22.602
Mar ’25NOK 37.00
NOK 49.00
+32.43%
2.04%NOK 50.00NOK 48.00NOK 21.002
Feb ’25NOK 38.50
NOK 49.00
+27.27%
2.04%NOK 50.00NOK 48.00NOK 24.402
Jan ’25NOK 36.70
NOK 49.00
+33.51%
2.04%NOK 50.00NOK 48.00NOK 25.702
Dec ’24NOK 38.50
NOK 49.00
+27.27%
2.04%NOK 50.00NOK 48.00NOK 25.602
Nov ’24NOK 38.90
NOK 47.00
+20.82%
6.38%NOK 50.00NOK 44.00NOK 25.002
Oct ’24NOK 39.30
NOK 47.00
+19.59%
6.38%NOK 50.00NOK 44.00NOK 30.102
Sep ’24NOK 32.00
NOK 47.00
+46.88%
6.38%NOK 50.00NOK 44.00NOK 29.102
Aug ’24NOK 36.80
NOK 50.50
+37.23%
4.95%NOK 53.00NOK 48.00NOK 32.002
Jul ’24NOK 38.50
NOK 49.00
+27.27%
8.16%NOK 53.00NOK 45.00NOK 33.002
Jun ’24NOK 37.90
NOK 49.00
+29.29%
8.16%NOK 53.00NOK 45.00NOK 33.902
May ’24NOK 36.40
NOK 50.00
+37.36%
10.00%NOK 55.00NOK 45.00NOK 32.402
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
NOK 34.00
Fair Value
34.7% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 04:19
End of Day Share Price 2025/05/12 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Navamedic ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Espen JørgensenDNB Markets
Gediminas RuginisNorne Securities AS
Juste SubataviciuteNorne Securities AS